Adia Med Files Provisional Patent for Breakthrough Regenerative Medical Protocol
ADIA Nutrition (OTCQB: ADIA) filed a provisional patent application with the United States Patent and Trademark Office on November 12, 2025 for a novel medical protocol aimed at enhancing regenerative outcomes.
The patent pending protocol reportedly uses unique procedural and biological mechanisms and gives ADIA a 12-month window to advance research, partnerships, and commercialization while preserving strategic confidentiality.
The company invited clinic owners and healthcare practitioners to inquire about licensing and integration of its regenerative therapies and said further updates will follow as development progresses.
ADIA Nutrition (OTCQB: ADIA) ha presentato una domanda di brevetto provvisorio presso l'Ufficio Statunitense per i Brevetti e i Marchi il 12 novembre 2025 per un nuovo protocollo medico volto a migliorare gli esiti rigenerativi.
Il protocollo in attesa di brevetto impiega meccanismi procedimentali e biologici unici e offre ad ADIA una finestra di 12 mesi per avanzare nella ricerca, nelle partnership e nella commercializzazione, mantenendo al contempo riservatezza strategica.
L'azienda ha invitato i proprietari di cliniche e i professionisti della sanità a informarsi sulle licenze e sull'integrazione delle sue terapie rigenerative e ha dichiarato che ulteriori aggiornamenti seguiranno man mano che lo sviluppo progredisce.
ADIA Nutrition (OTCQB: ADIA) presentó una solicitud de patente provisional ante la Oficina de Patentes y Marcas de Estados Unidos el 12 de noviembre de 2025 para un protocolo médico novedoso destinado a mejorar los resultados regenerativos.
El protocolo pendiente de patente aparentemente utiliza mecanismos procedimentales y biológicos únicos y otorga a ADIA una ventana de 12 meses para avanzar en la investigación, asociaciones y comercialización, al tiempo que mantiene la confidencialidad estratégica.
La empresa invitó a los dueños de clínicas y a los profesionales de la salud a consultar sobre licencias e integración de sus terapias regenerativas y afirmó que se darán más actualizaciones a medida que avance el desarrollo.
ADIA Nutrition (OTCQB: ADIA)은/는 미국 특허상표청에 2025년 11월 12일에 새로운 의학 프로토콜에 대한 임시 특허 출원을 했다고 밝혔다. 이 프로토콜은 재생 결과를 향상시키는 것을 목표로 한다.
특허 대기 중인 이 프로토콜은 독특한 절차적 및 생물학적 메커니즘을 사용하는 것으로 보이며 ADIA에 연구, 파트너십 및 상용화를 위한 12개월의 창을 제공하면서 전략적 기밀을 유지한다.
회사는 클리닉 소유주와 의료 종사자들에게 재생 치료의 라이선스 및 통합에 대해 문의하도록 초대했고 개발 진행에 따라 추가 업데이트가 이어질 것이라고 말했다.
ADIA Nutrition (OTCQB: ADIA) a déposé une demande de brevet provisoire auprès de l'Office américain des brevets et des marques le 12 novembre 2025 pour un nouveau protocole médical visant à améliorer les résultats régénératifs.
Le protocole en attente de brevet utilise apparemment des mécanismes procéduraux et biologiques uniques et donne à ADIA une fenêtre de 12 mois pour faire progresser la recherche, les partenariats et la commercialisation tout en préservant la confidentialité stratégique.
L'entreprise a invité les propriétaires de cliniques et les praticiens de la santé à se renseigner sur les licences et l'intégration de ses thérapies régénératives et a indiqué que d'autres mises à jour suivront au fur et à mesure de l'avancement du développement.
ADIA Nutrition (OTCQB: ADIA) hat am 12. November 2025 einen vorläufigen Patentantrag beim US-Patent- und Markenamt eingereicht für ein neuartiges medizinisches Protokoll zur Verbesserung regenerativer Ergebnisse.
Das patent pending Protokoll verwendet Berichten zufolge einzigartige Verfahrens- und biologische Mechanismen und verschafft ADIA ein 12-monatiges Fenster, um Forschung, Partnerschaften und Kommerzialisierung voranzutreiben, während die strategische Vertraulichkeit gewahrt bleibt.
Das Unternehmen lud Klinikinhaber und Gesundheitsdienstleister ein, sich über Lizenzen und die Integration seiner regenerativen Therapien zu informieren, und sagte, dass weitere Updates folgen werden, während die Entwicklung fortschreitet.
ADIA Nutrition (OTCQB: ADIA) قدمت طلب براءة اختراع مؤقت لدى مكتب الولايات المتحدة للبراءات والعلامات التجارية في 12 نوفمبر 2025 لبروتوكول طبي جديد يهدف إلى تعزيز نتائج التجديد.
يستخدم بروتوكول قيد البراءة كما يبدو آليات إجرائية وبيولوجية فريدة ويمنح ADIA نافذة 12 شهرًا لتطوير البحث والشراكات والتسويق مع الحفاظ على السرية الاستراتيجية.
دعت الشركة مالكي العيادات وممارسي الرعاية الصحية للاستفسار عن التراخيص ودمج علاجاتها التجديدية وقالت إن هناك تحديثات إضافية ستتبع مع تقدم التطوير.
- Provisional patent filed with USPTO on November 12, 2025
- Patent pending grants 12 months to advance research and partnerships
- Company positions itself as a leader in regenerative medicine IP
- Provisional filing is not an issued patent and may not be granted
- No clinical trial results or quantitative efficacy data disclosed
Winter Park, Florida--(Newsfile Corp. - November 12, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced regenerative health solutions, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO) for a novel medical protocol designed to enhance regenerative outcomes.
This Patent Pending innovation represents a significant advancement in ADIA's mission to deliver cutting-edge, science-backed therapies. The proprietary protocol leverages unique procedural and biological mechanisms previously unexplored in clinical practice, positioning the company at the forefront of regenerative medicine.
"Securing this provisional patent marks a pivotal step in protecting our intellectual property while accelerating development of next-generation health solutions," Larry Powalisz, CEO of Adia Nutrition. "This filing underscores ADIA's commitment to innovation that delivers real clinical value."
The Patent Pending status allows ADIA to advance research, partnerships, and commercialization pathways over the next 12 months while maintaining strategic confidentiality.
ADIA Nutrition plans to provide further updates as development progresses.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, AdiaLabs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273994
FAQ
What did ADIA (OTCQB: ADIA) announce on November 12, 2025?
What does the ADIA provisional patent mean for investors and partners?
Does ADIA's provisional patent guarantee a granted patent for the protocol?
Can clinic owners license ADIA's regenerative therapies now?
Who should investors contact for more information about ADIA's patent filing?
Will ADIA provide clinical data or updates about the protocol timeline?
